Differential gene expression profiles of PPP2R5C-siRNA-Treated malignant T cells

DNA and Cell Biology

Volumn 32, Issue 10, 2013, Pages 573-581

  Chen, Yu ^a,b   Liu, Sichu ^b   Shen, Qi ^b   Zha, Xianfeng ^b,c   Zheng, Haitao ^b   Yang, Lijian ^b   Chen, Shaohua ^b   Wu, Xiuli ^b   Li, Bo ^b   Li, Yangqiu ^a,b  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHOLECYSTOKININ OCTAPEPTIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOCORTIN 5; MESSENGER RNA; PROTEIN MDM2; SMALL INTERFERING RNA;

ARTICLE; CELL PROLIFERATION; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; PPP2R5C GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T LYMPHOCYTE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; EXONS; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN PHOSPHATASE 2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84884283820     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2138     Document Type: Article

References (50)

1. Aifantis, I., Raetz, E., and Buonamici, S. (.2008). Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8, 380-390
2. Arce, L., Yokoyama, N.N., and Waterman, M.L. (.2006). Diversity of LEF/TCF action in development and disease. Oncogene 25, 7492-7504
3. Chen, S., Huang, X., Chen, S.H., Yang, L., Shen, Q., Zheng, H., Li, B., Grabarczyk, P., Przybylski, G.K., Schmidt, C.A., and Li, Y. (.2012). The role of BCL11B in regulating the proliferation of human naïve T cells. Hum Immunol 73, 456-464
4. Cioca, D.P., Aoki, Y., and Kijosawa, K. (.2003). RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 10, 125-133
5. Devi, R.S. (.2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther 13, 819-829
6. Ditch, S., and Paull, T.T. (.2012). The ATM protein kinase and cellular redox signaling: Beyond the DNA damage response. Trends Biochem Sci 37, 5-22
7. Elbashir, S., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (.2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498
8. Gattinoni, L., Ji, Y., and Restifo, N.P. (.2010). Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res 16, 4695-4701
9. Grabarczyk, P., Przybylski, G.K., Depke, M., Völker, U., Bahr, J., Assmus, K., Bröker, B.M., Walther, R., and Schmidt, C.A. (.2007). Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 26, 3797-3810
10. Graham, D.K., Salzberg, D.B., and Kurtzberg, J. (.2006). Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 12, 2662-2669
11. Guo, D., Ye, J., Dai, J., Li, L., Chen, F., Ma, D., and Ji, C. 2009 Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in TALL cell lines. Leuk Res 33, 678-685
12. Huang, X., Chen, S. Shen, Q., Chen, S., Yang, L., Grabarczyk, P., Przybylski, G.K., Schmidt, C.A., and Li, Y. (.2011a). Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA. Hematology 6, 236-242
13. Huang, X., Shen, Q., Chen, S., Chen, S., Yang, L., Weng, J., Du, X., Grabarczyk, P., Przybylski, G.K., Schmidt, C.A., and Li Y. (.2011b). Gene expression profiles in BCL11B-siRNA treated malignant T cells. J Hematol Oncol 4, 23
14. Ishida, T., and Ueda, R. (.2006). CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97, 1139-1146
15. Isin, M., Yenerel, M., Aktan, M., Buyru, N., and Dalay, N. 2012 Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia. DNA Cell Biol 31, 777-782
16. Kanehisa, M. (.2002). The KEGG database. Novartis Found Symp 247, 91-101; discussion 101-103, 119-128, 244-152
17. Labbaye, C., and Testa, U. (.2012). The emerging role of MIR- 146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol 5, 13
18. Laky, K., Fleischacker, C., and Fowlkes, B.J. (.2006). TCR and Notch signaling in CD4 and CD8 T-cell development. Immunol Rev 209, 274-283
19. Lai, P., Weng, J., Lu, Z., Guo, R., Luo, C., Wu, S., Ling, W., Geng, S., and Du, X. (.2011). Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease. DNA Cell Biol 30, 1019-1025
20. Lee, T.Y., Lai, T.Y., Lin, S.C.,Wu, C.W., Ni, I.F., Yang, Y.S., Hung, L.Y., Law, B.K., and Chiang, C.W. (.2010). The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem 285, 21567-21580
21. Li, H.H., Cai, X., Shouse, G.P., Piluso, L.G., and Liu, X. (.2007). A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 26, 402-411
22. Lin, S.S., Bassik, M.C., Suh, H., Nishino, M., Arroyo, J.D., Hahn, W.C., Korsmeyer, S.J., and Roberts, T.M. (.2006). PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 281, 23003-23012
23. Liu, P., Li, P., and Burke, S. (.2010). Critical roles of Bcl11b in Tcell development and maintenance of T-cell identity. Immunol Rev 238, 138-149
24. MacDonald, B.T., Tamai, K., and He, X. (.2009). Wnt/betacatenin signaling: Components, mechanisms, and diseases. Dev Cell 17, 9-26
25. Muneer, S., Ramalingam, V., Wyatt, R., Schultz, R.A., Minna, J.D., and Kamibayashi, C. (.2002). Genomic organization and mapping of the gene encoding the PP2A B56gamma regulatory subunit. Genomics 79, 344-348
26. Oh, Y.K., and Park, T.G. (.2009). siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61, 850-862
27. Oshiro, A., Tagawa, H., Ohshima, K., Karube, K., Uike, N., Tashiro, Y., Utsunomiya, A., Masuda, M., Takasu, N., Nakamura, S., Morishima, Y., and Seto, M. (.2006). Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107, 4500-4507
28. Peipp, M., Kü pers, H., Saul, D., Schlierf, B., Greil, J., Zunino, S.J., Gramatzki, M., and Fey, G.H. (.2002). A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 62, 2848-2855
29. Palomero, T., and Ferrando, A. (.2009). Therapeutic targeting of NOTCH1 signaling in T-ALL. Clin Lymphoma Myeloma 9(Suppl 3), S205
30. Ravandi, F., and O'Brien, S. (.2006). Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 24, 718-725
31. Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A., and Kutok, J.L. (.2006). Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)]. Clin Cancer Res 12, 7174-7179
32. Sato, T., and Yamochi, T. (.2005). CD26 regulates p38 mitogenactivated protein kinase-dependent phosphorylation of integrin beta, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 65, 6950-6956
33. Seeling, J.M., Miller, J.R., Gil, R., Moon, R.T., White, R., and Virshup, D.M. (.1999). Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283, 2089-2091
34. Shouse, G.P., Cai, X., and Liu, X. (.2008). Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol 28, 448-456
35. Shouse, G.P., Nobumori, Y., and Liu, X. (.2010). A B56gamma mutation in lung cancer disrupts the p53-dependent tumorsuppressor function of protein phosphatase 2A. Oncogene 29, 3933-3941
36. Shouse, G.P., Nobumori, Y., Panowicz, M.J., and Liu, X. 2011 ATM-mediated phosphorylation activates the tumorsuppressive function of B56g-PP2A. Oncogene 30, 3755-3765
37. Tiemessen, M.M., Baert, M.R., Schonewille, T., Brugman, M.H., Famili, F., Salvatori. D.C., Meijerink, J.P., Ozbek, U., Clevers, H., van Dongen, J.J., and Staal, F.J. (.2012). The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol 10, e1001430
38. Torgersen, K.M., Aandahl, E.M., and Tasken, K. (.2008). Molecular architecture of signal complexes regulating immune cell function. Handb Exp Pharmacol 2008, 327-363
39. Uhrinova, S., Uhrin, D., Powers, H.,Watt, K., Zheleva, D., Fischer, P., McInnes, C., and Barlow, P.N. (.2005). Structure of free MDM2N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350, 587-598
40. Varisli, L., Gonen-Korkmaz, C., Debelec-Butuner, B., Erbaykent- Tepedelen, B., Muhammed, H.S., Bogurcu, N., Saatcioglu, F., and Korkmaz, K.S. (.2011). Ubiquitously expressed hematological and neurological expressed 1 downregulates Aktmediated GSK3b signaling, and its knockdown results in deregulated G2/M transition in prostate cells. DNA Cell Biol 30, 419-429
41. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E.A. (.2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848
42. Wang, K., Wei, G., and Liu, D. (.2012). CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1, 36
43. Whitehead, K.A., Langer, R., and Anderson, D.G. 2009 Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8, 129-138
44. Wilkinson, B., Downey, J.S., and Rudd, C.E. (.2005). T-cell signalling and immune systemdisorders. Expert Rev MolMed 7, 1-29
45. Xue, H.H., and Zhao, D.M. (.2012). Regulation of mature T cell responses by the Wnt signaling pathway. Ann N Y Acad Sci 1247, 16-33
46. Yang, J., and Phiel, C. (.2010). Functions of B56-containing PP2As in major developmental and cancer signaling pathways. Life Sci 87, 659-666
47. Zha, X., Chen, S., Yang, L., Shi, L., Li, B., Wu, X., Lu, Y., and Li, Y. (.2012). Up-regulated TCRz enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol 31, 1628-1635
48. Zha, X., Yin, Q., Tan, H., Wang, C., Chen, S., Yang, L., Li, B., Wu, X., and Li, Y. (.2013). Alteration of the gene expression profile of TCRab-modified T-cells with DLBCL specificity. Hematology 18, 138-143
49. Zheng, H., Chen, Y., Chen, S., Niu, Y., Yang, L., Li, B., Lu, Y., Geng, S., Du, X., and Li, Y. (.2011). Expression and distribution of the PPP2R5C gene in leukemia. J Hematol Oncol, 4, 21
50. Zinzani, P.L., Khuageva, N.K., Wang, H., Garicochea, B., Walewski, J., Van Hoof, A., Soubeyran, P., Caballero, D., Buckstein, R., Esseltine, D.L., Theocharous, P., Enny, C., Zhu, E., Elsayed, Y.A., and Coiffier, B. (.2012). Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial. J Hematol Oncol 5, 67